CAR T-Cell Therapy Yields High Response Rate in Aggressive LymphomaCancer NetworkIn this video, Frederick Locke, MD, of the Moffitt Cancer Center in Tampa, Florida, discusses results of the ZUMA-1 trial, which tested chimeric antigen receptor (CAR) T-c… Continue reading
Continued Immunotherapy Could Be Effective Despite ProgressionSpecialty Pharmacy TimesAlthough immunotherapy has transformed the oncology world, the drugs may not be effective in certain cases. Traditionally, when cancer progresses, the physician will … Continue reading
PLoS Blogs (blog)Interpreting Electrocardiograms, Designing CRISPR sgRNAs, and Improving New Analyses of Old MRI Data: the PLOS …PLoS Blogs (blog)CRISPR-Cas9 technology can be used to engineer precise genomic deletions with pairs of single guide RNAs… Continue reading
Targeted Oncology |
CAR T Cell Functionality Found to Correlate With Outcomes for Patients With Melanoma
Targeted Oncology A retrospective analysis presented at the 2017 AACR Annual Meeting found the flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma. In the … |
Targeted Oncology |
CAR T Cell Functionality Found to Correlate With Outcomes for Patients With Melanoma
Targeted Oncology A retrospective analysis presented at the 2017 AACR Annual Meeting found the flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma. In the … |
|
PET radiotracer design for monitoring targeted immunotherapy Society of Nuclear Medicine
EurekAlert (press release) A drug that blocks a cancer’s inhibitory checkpoint molecules is called an immune checkpoint inhibitor and this form of immunotherapy has emerged as a promising cancer treatment approach. However, the lack of imaging tools to assess immune checkpoint … |
R & D Magazine |
Stem Cell Drug Screen Yields Potential Alternative to Statins
R & D Magazine In a study appearing in the April 6, 2017 issue of Cell Stem Cell, cardiac glycosides reduced levels of a precursor of LDL in liver-like cells, and patients taking cardiac glycosides for heart failure had low LDL. Not everyone with high LDL cholesterol … |
|
IsoPlexis research offers hope for targeted CAR–T treatment
The Pharma Letter (registration) US-based biotech firm IsoPlexis has presented findings from research using the company’s precision engineering platform, called IsoCode. The data show the potential to predict whether cancer patients will respond to CAR–T cell therapy prior to … |